125 related articles for article (PubMed ID: 36087032)
1. Overexpression of NIMA related kinase 2 in multiple myeloma and its relevance with disease features and prognosis to bortezomib treatment.
Gu X; Wang Z; Pan Q
J Clin Pharm Ther; 2022 Oct; 47(10):1690-1697. PubMed ID: 36087032
[TBL] [Abstract][Full Text] [Related]
2. Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.
Feng X; Guo J; An G; Wu Y; Liu Z; Meng B; He N; Zhao X; Chen S; Zhu Y; Xia J; Li X; Yu Z; Li R; Ren G; Chen J; Wu M; He Y; Qiu L; Zhou J; Zhou W
Adv Sci (Weinh); 2022 Mar; 9(9):e2104491. PubMed ID: 35088582
[TBL] [Abstract][Full Text] [Related]
3. NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma.
Xia J; He Y; Meng B; Chen S; Zhang J; Wu X; Zhu Y; Shen Y; Feng X; Guan Y; Kuang C; Guo J; Lei Q; Wu Y; An G; Li G; Qiu L; Zhan F; Zhou W
Mol Oncol; 2020 Apr; 14(4):763-778. PubMed ID: 31955515
[TBL] [Abstract][Full Text] [Related]
4. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.
Franqui-Machin R; Hao M; Bai H; Gu Z; Zhan X; Habelhah H; Jethava Y; Qiu L; Frech I; Tricot G; Zhan F
J Clin Invest; 2018 Jul; 128(7):2877-2893. PubMed ID: 29863498
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Nek2 by small molecules affects proteasome activity.
Meng L; Carpenter K; Mollard A; Vankayalapati H; Warner SL; Sharma S; Tricot G; Zhan F; Bearss DJ
Biomed Res Int; 2014; 2014():273180. PubMed ID: 25313354
[TBL] [Abstract][Full Text] [Related]
6. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.
Li X; Yang Y; Yi X
Technol Cancer Res Treat; 2020; 19():1533033820936770. PubMed ID: 32799769
[TBL] [Abstract][Full Text] [Related]
7. Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for bortezomib response and prognosis in multiple myeloma patients.
Zhou F; Guo L
Hematology; 2022 Dec; 27(1):596-602. PubMed ID: 35617291
[TBL] [Abstract][Full Text] [Related]
8. NIMA related kinase 2 promotes gastric cancer cell proliferation
Fan WD; Chen T; Liu PJ
World J Gastroenterol; 2019 Jun; 25(23):2898-2910. PubMed ID: 31249448
[TBL] [Abstract][Full Text] [Related]
9. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
Yu Z; Wei X; Liu L; Sun H; Fang T; Wang L; Li Y; Sui W; Wang K; He Y; Zhao Y; Huang W; An G; Meng F; Huang C; Yu T; Anderson KC; Cheng T; Qiu L; Hao M
EBioMedicine; 2022 Apr; 78():103950. PubMed ID: 35344764
[TBL] [Abstract][Full Text] [Related]
10. Spliced X-Box binding protein 1 predicts satisfying responsiveness and survival benefit toward bortezomib-based therapy in multiple myeloma patients.
Zhang L; Gong J; Yaqiong L
Hematology; 2022 Dec; 27(1):1102-1109. PubMed ID: 36121128
[TBL] [Abstract][Full Text] [Related]
11. PCAT1 promotes the proliferative and migratory potentials of ovarian cancer via targeting NEK2.
Liu XL; Liu HM; Han N; Li FH; Sun F; Fan DM; Xu Q
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8239-8248. PubMed ID: 31646554
[TBL] [Abstract][Full Text] [Related]
12. High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.
Chen C; Peng S; Li P; Ma L; Gan X
Mol Cell Biochem; 2020 Dec; 475(1-2):15-25. PubMed ID: 32761510
[TBL] [Abstract][Full Text] [Related]
13. Cell division cycle 37 change after bortezomib-based induction therapy helps to predict clinical response and prognosis in multiple myeloma patients.
Lin W; Chen X; Zheng H; Cai Z
Hematology; 2023 Dec; 28(1):2231741. PubMed ID: 37409850
[TBL] [Abstract][Full Text] [Related]
14. Deguelin inhibits epithelial-to-mesenchymal transition and metastasis of human non-small cell lung cancer cells by regulating NIMA-related kinase 2.
Zhao D; Han W; Liu X; Cui D; Chen Y
Thorac Cancer; 2017 Jul; 8(4):320-327. PubMed ID: 28509438
[TBL] [Abstract][Full Text] [Related]
15. PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling.
Xu B; Li J; Xu D; Ran Q
Ir J Med Sci; 2023 Apr; 192(2):561-567. PubMed ID: 35508865
[TBL] [Abstract][Full Text] [Related]
16. Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines.
Zeissig MN; Hewett DR; Mrozik KM; Panagopoulos V; Wallington-Gates CT; Spencer A; Dold SM; Engelhardt M; Vandyke K; Zannettino ACW
Leuk Res; 2024 Apr; 139():107469. PubMed ID: 38479337
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer.
Zeng YR; Han ZD; Wang C; Cai C; Huang YQ; Luo HW; Liu ZZ; Zhuo YJ; Dai QS; Zhao HB; Liang YX; Zhong WD
BMC Urol; 2015 Aug; 15():90. PubMed ID: 26320076
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma.
Liu H; Liu B; Hou X; Pang B; Guo P; Jiang W; Ding Q; Zhang R; Xin T; Guo H; Xu S; Pang Q
J Neurooncol; 2017 May; 132(3):409-417. PubMed ID: 28321704
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human p53 adenovirus injection combined with Bortezomib inhibits proliferation and promotes apoptosis in multiple myeloma.
Wang Q; Shi Q; Chen Y; Wang G; Shen L
Leuk Res; 2023 Apr; 127():107041. PubMed ID: 36801701
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of NEK2 in human solid tumors: a systematic review and meta-analysis.
Wang X; Chen K; Liu H; Huang Z; Chen X; Yin L
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30578380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
